Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Published Online
on December 1, 2003

Hypertension. 2003
Published online before print December 1, 2003, doi: 10.1161/01.HYP.0000105623.04382.C0
A more recent version of this article appeared on January 1, 2004
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
43/1/94    most recent
01.HYP.0000105623.04382.C0v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wright, S. P.
Right arrow Articles by Richards, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wright, S. P.
Right arrow Articles by Richards, M.

Submitted on July 18, 2003
Revised on August 13, 2003

Amino-Terminal Pro-C-Type Natriuretic Peptide in Heart Failure

Sue P. Wright; Tim C.R. Prickett; Robert N. Doughty; Chris Frampton; Greg D. Gamble; Tim G. Yandle; Norman Sharpe; and Mark Richards*

From the Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, New Zealand, and Christchurch Cardioendocrine Research Group, Department of Medicine, Christchurch School of Medicine and Health Sciences, University of Otago, Christchurch, New Zealand.

* To whom correspondence should be addressed. E-mail: mark.richards{at}cdhb.govt.nz.

Abstract--The levels and pathophysiological role of amino terminal C-type natriuretic peptide in heart failure are unknown. The potential of plasma amino-terminal C-type natriuretic peptide (N-CNP) as a marker of cardiac function was investigated in symptomatic patients. In 305 patients with recent-onset dyspnea and/or peripheral edema, presenting to primary care, assay of plasma amino-terminal C-type natriuretic peptide and other plasma vasoactive hormones was conducted together with echocardiography. Heart failure was diagnosed in 77 (of the 305) patients by rigorous application of predefined criteria. Plasma amino-terminal C-type natriuretic peptide concentrations were elevated in patients with heart failure, and by univariate analysis were related to age, renal function, and other hormones. On multivariate analysis, tertile of plasma N-CNP interacted with tertile of plasma amino-terminal B-type natriuretic peptide to predict heart failure independent of age, gender, renal function, or echocardiographic left ventricular fractional shortening. N-CNP showed significant relations to concurrent plasma CNP, atrial natriuretic peptide (ANP), N-ANP, B-type (or brain) natriuretic peptide (BNP), N-BNP, endothelin-1, and adrenomedullin but not to echocardiographic indicators of left ventricular systolic function. Plasma amino-terminal C-type natriuretic peptide is elevated in heart failure and is related to other plasma hormones in heart failure. These findings suggest a possible compensatory response from the peripheral vasculature to heart failure by an endothelium-based vasodilator peptide and mandate further exploration of the role of C-type natriuretic peptide in this condition.


Key words: natriuretic peptides • heart failure • echocardiography • hormones




This article has been cited by other articles:


Home page
HypertensionHome page
S. C. Palmer, T. C.R. Prickett, E. A. Espiner, T. G. Yandle, and A. M. Richards
Regional Release and Clearance of C-Type Natriuretic Peptides in the Human Circulation and Relation to Cardiac Function
Hypertension, September 1, 2009; 54(3): 612 - 618.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
R J Hillock, C M Frampton, T G Yandle, R W Troughton, J G Lainchbury, and A M Richards
B-type natriuretic peptide infusions in acute myocardial infarction
Heart, May 1, 2008; 94(5): 617 - 622.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
A. M. Richards
Natriuretic Peptides: Update on Peptide Release, Bioactivity, and Clinical Use
Hypertension, July 1, 2007; 50(1): 25 - 30.
[Full Text] [PDF]


Home page
HeartHome page
C H Strey, J M Young, J H Lainchbury, C M Frampton, M G Nicholls, A M Richards, and R S Scott
Short-term statin treatment improves endothelial function and neurohormonal imbalance in normocholesterolaemic patients with non-ischaemic heart failure
Heart, November 1, 2006; 92(11): 1603 - 1609.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
L. R. Potter, S. Abbey-Hosch, and D. M. Dickey
Natriuretic Peptides, Their Receptors, and Cyclic Guanosine Monophosphate-Dependent Signaling Functions
Endocr. Rev., February 1, 2006; 27(1): 47 - 72.
[Abstract] [Full Text] [PDF]


Home page
Eur J Heart FailHome page
S. Del Ry, C. Passino, M. Maltinti, M. Emdin, and D. Giannessi
C-type natriuretic peptide plasma levels increase in patients with chronic heart failure as a function of clinical severity
Eur J Heart Fail, December 1, 2005; 7(7): 1145 - 1148.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
S. J. Nielsen, J. F. Rehfeld, F. Pedersen, J. Kastrup, R. Videbaek, and J. P. Goetze
Measurement of Pro-C-Type Natriuretic Peptide in Plasma
Clin. Chem., November 1, 2005; 51(11): 2173 - 2176.
[Full Text] [PDF]